These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 21829020

  • 21. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

  • 22. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R, Byrne MT, Tan A, Aucejo F.
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [Abstract] [Full Text] [Related]

  • 23. [Hepatocellular carcinoma].
    Kondo S, Ueno H, Morizane C, Okusaka T.
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
    [Abstract] [Full Text] [Related]

  • 24. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
    Cheng AL, Shen YC, Zhu AX.
    Oncology; 2011 Jul; 81(5-6):372-80. PubMed ID: 22269894
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Systemic therapies in hepatocellular carcinoma.
    Wörns MA, Weinmann A, Schuchmann M, Galle PR.
    Dig Dis; 2009 Jul; 27(2):175-88. PubMed ID: 19546557
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT.
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Management of advanced hepatocellular carcinoma in the era of targeted therapy.
    Yau T, Chan P, Epstein R, Poon RT.
    Liver Int; 2009 Jan; 29(1):10-7. PubMed ID: 19120940
    [Abstract] [Full Text] [Related]

  • 31. Molecular targeting for treatment of advanced hepatocellular carcinoma.
    Song IH.
    Korean J Hepatol; 2009 Sep; 15(3):299-308. PubMed ID: 19783879
    [Abstract] [Full Text] [Related]

  • 32. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
    Lencioni R, Chen XP, Dagher L, Venook AP.
    Oncologist; 2010 Sep; 15 Suppl 4():42-52. PubMed ID: 21115580
    [Abstract] [Full Text] [Related]

  • 33. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H.
    Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
    [Abstract] [Full Text] [Related]

  • 34. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V, Barbare JC, Rosmorduc O, Groupe de travail carcinome hépatocellulaire Prodige-Afef.
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Growth factors as therapeutic targets in HCC.
    Furuse J.
    Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. New drugs for the treatment of hepatocellular carcinoma.
    Boucher E, Forner A, Reig M, Bruix J.
    Liver Int; 2009 Jan; 29 Suppl 1():148-58. PubMed ID: 19207980
    [Abstract] [Full Text] [Related]

  • 40. Latest developments in targeted therapy for hepatocellular carcinoma.
    Montella L, Addeo R, Caraglia M, Del Prete S.
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1635-46. PubMed ID: 20942634
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.